The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] 35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res 10:1217-1221 sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] 75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fuku- shima K, Krozowski ZS 1996 Localization of 11-hydroxysteroid dehydro- genase type II in human epithelial tissues. J Clin Endocrinol Metab 81:3244 - 3248 source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] 51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cav- agnini F 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123- 4129 source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] 30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120: e575-e586 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 1,501–1,600 of 2,716
Factors affecting early versus late remission in acromegaly following stereotactic radiosurgery
Patibandla, M. R., Xu, Z., & Sheehan, J. P. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2792-x · Cited by 6
Evaluation and Treatment of Adrenal Dysfunction in the Primary Care Environment
Cole, S. (2018) · Nursing Clinics of North America · doi:10.1016/j.cnur.2018.04.007 · Cited by 6
Midnight salivary cortisol for the diagnosis of Cushing’s syndrome in a Chinese population
Lin, D., Tsai, P., & Lin, Y. (2019) · Singapore Medical Journal · doi:10.11622/smedj.2018154 · Cited by 6
Pediatric Obesity: Endocrinologic and Genetic Etiologies and Management
Gowda, S. H., Seibert, T. S., Uli, N. K., & Farrell, R. (2019) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-019-0632-y · Cited by 6
Advances in the Diagnosis and Medical Management of Cushing's Syndrome
Delivanis, D. A., Sharma, A. R., Hamidi, O., Shah, M., & Bancos, I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66195-9.00015-7 · Cited by 6
Glyn, T., Ho, M., Lambert, A. P., Thomas, J., Douek, I. F., Andrews, R. C., & King, R. (2020) · Clinical Obesity · doi:10.1111/cob.12358 · Cited by 6
“All of these tests have adequate sensitivity for use as initial screening tools and are recommended as the initial test by The Endocrine Society for use in ‘patients with multiple and progressive features compatible with the syndrome’.(4) No advice is given about routine screening in different circumstances.”
MethodAdrenal Causes of Hypercortisolism
Cavagnini, F., & Giraldi, F. P. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00102-7 · Cited by 5
Bleier, J., Shlomai, G., Fishman, B., Dotan, Z., Rosenzweig, B., & Tirosh, A. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0111 · Cited by 6
Oral pathology induced by excess or deficiency of glucocorticoids in adults
Miulescu, R. D., Guja, L., Socea, B., Dumitriu, A. S., Păunica, S., & Ștefănescu, E. (2020) · Journal of Mind and Medical Sciences · doi:10.22543/7674.72.p141147 · Cited by 7
“In individuals with abnormal test results, the following investigations are recommended: random serum cortisol or ACTH levels, urinary 17ketosteroids, pituitary and adrenal imaging, and 8 mg dexamethasone suppression test [28].”
BackgroundNewman, C., Costello, M. M., Casey, M., Davern, R., Dinneen, K., Lowery, A., McHale, T., O’Shea, P. M., Quinn, A. M., & Bell, M. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211030160 · Cited by 7
Fernández, L. G., Ramos, R. J. A., Montenegro, A. M. R., Torrecilla, N. B., González, M. M., Moreno, D. M., Goñi, J. A., Weber, B., Guerra, A. L., Ishishi, Y. L. O., et al. (2021) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2021.10.006 · Cited by 6
Zhang, D., Lü, L., Zhu, H., Xiao, Y. P., Han, X., Du, S., Xue, H., Liu, Q., Zhu, Z., Hu, M., et al. (2022) · International Journal of Endocrinology · doi:10.1155/2022/6283706 · Cited by 6
Durmuş, E. T., Atmaca, A., Uzunkaya, F., Çolak, R., & Durmuş, B. (2022) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.5500 · Cited by 7
“All patients met the diagnostic criteria for CS as given in the clinical practice guidelines of the Endocrine Society [6].”
MethodFraser, L.-A., & Uum, S. H. M. V. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.090250 · Cited by 5
“Testing at least twice for cortisol levels in urine and saliva is recommended.(1) Abnormal test results should prompt referral to an endocrinologist for an assessment of the likelihood of Cushing syndrome.”
BackgroundMethodInfluentialWitek, P., Zieliński, G., Szamotulska, K., & Zgliczyński, W. (2013) · PubMed · Cited by 5
Three Novel MEN1 Variants in AIP-Negative Familial Isolated Pituitary Adenoma Patients
Yarman, S., Tuncer, F. N., & Serbest, E. (2019) · Pathobiology · doi:10.1159/000495252 · Cited by 5
Fan, J. (2013) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2013.v2.1.24 · Cited by 5
“Moreover, previously used criteria have varied (15-17).”
Determinación de los niveles de cortisol salival en una muestra de sujetos de Santiago de Chile
Lépez, M., Caamaño, E., Romero, C., Fiedler, J. L., & Araya, V. (2010) · Revista médica de Chile · doi:10.4067/s0034-98872010000200004 · Cited by 15
Case 17-2013: A 56-Year-Old Woman with Poorly Controlled Diabetes Mellitus and Fatigue
Florez, J. C., Shepard, J.-A. O., & Kradin, R. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmcpc1215971 · Cited by 5
Dorizzi, R. M., Ferrari, A. M., Vitillo, M., Caruso, B., Cocco, C., Ciotoli, E., D’Aurizio, F., Esposito, E., Giannone, G., Ozzola, G., et al. (2016) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.1007/s13631-016-0115-9 · Cited by 5
“L'Endocrine Society raccomanda il monitoraggio dei livelli di 25OH-D nei soggetti a rischio di deficienza (soggetti con sospetta o nota patologia da malassorbimento , soggetti immobilizzati e/o che non si espongono alla luce solare, soggetti di pelle scura che vivono in Paesi a latitudini superiori al 33° parallelo, s…”
BackgroundInfluentialGuidelines for the management of the incidentally discovered adrenal mass
Kapoor, A., Morris, T., & Rebello, R. (2013) · Canadian Urological Association Journal · doi:10.5489/cuaj.657 · Cited by 6
Endocrine Disorders that Cause Diabetes
Jennings, R. E., & Hanley, N. A. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch20 · Cited by 5
Letter to the Editor: Cushing's disease and dural invasion
Hueng, D., Ma, H., & Chen, C. (2012) · Journal of neurosurgery · doi:10.3171/2012.2.jns111890 · Cited by 5
Jurek, A., Krzesiński, P., Uziębło‐Życzkowska, B., Witek, P., Zieliński, G., Kazimierczak, A., Wierzbowski, R., Banak, M., & Gielerak, G. G. (2025) · Scientific Reports · doi:10.1038/s41598-024-84888-x · Cited by 6
Changes in clinical features of adrenal Cushing syndrome: a national registry study
Katabami, T., Asai, S., Matsuba, R., Sone, M., Izawa, S., Ichijo, T., Tsuiki, M., Okamura, S., Yoshimoto, T., Otsuki, M., et al. (2025) · Endocrine Connections · doi:10.1530/ec-24-0684 · Cited by 7
“Therefore, as recommended by clinical guidelines (29) Finally, all but one patient (97.3”
InfluentialBioletto, F., Bogeat, C., Barat, M., Benanteur, N., Guignat, L., Hage, M. P., Garcia, C., Calugaru, V., Jacob, J., Arrondeau, J., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf136 · Cited by 4
Beyond the Classical Axis: Metabolic “Pressure” on the Adrenal Gland?
Isidori, A. M., Pofi, R., & Fleseriu, M. (2025) · Diabetes · doi:10.2337/dbi25-0035 · Cited by 5
“Importantly, society guidelines and expert opinions almost unanimously (7–10) recommend against routine screening for endogenous CS unless specific clinical features raise suspicion (e.g., facial plethora, proximal myopathy, adrenal inci-dentalomas, resistant hypertension, early-onset osteoporosis).”
Chacko, S. R., Ahmadian, S., Sharma, S. S., Saini, J., Fell, V. M., Achenbach, S. J., Atkinson, E., Gompel, J. J. V., Young, W. F., & Bancos, I. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf264 · Cited by 5
Plutzky, J., Taub, P. R., Bhatt, D. L., Dhaybi, O. A., Aroda, V. R., BASILE, J. N., Bloch, M. J., Budoff, M. J., Busch, R. S., Buse, J. B., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102596 · Cited by 7
Resistant hypertension, hyperaldosteronism, and the emerging understanding of hypercortisolism
EINHORN, D. F., Mende, C. W., & Auchus, R. J. (2026) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001315 · Cited by 4
Muscogiuri, G., Albertelli, M., Arnaldi, G., Barrea, L., Bellastella, G., Bonomi, M., Caputo, M., Caprio, M., Cignarelli, A., Gioia, L. D., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02862-y · Cited by 4
Rethinking hypercortisolism screening in obesity and diabetes: A systematic review and meta-analysis
Ferrari, D., Bonaventura, I., Tenuta, M., Pofi, R., Awadi, F. A., Jamal, H. F., Pivonello, R., Corona, G., & Isidori, A. M. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156675 · Cited by 4
Principles of management of women with hirsutism – a dermatologist’s perspective
Mikiel, D., Olszewska, B., Polańska, A., Adamski, Z., Żaba, R. W., & Dańczak‐Pazdrowska, A. (2020) · Dermatology Review · doi:10.5114/dr.2020.101670 · Cited by 7
Damianse, S. D. S. P., Nascimento, G. C., Rocha, V. C. D. C., Nascimento, A. G., Gaido, N. C., Azulay, R. S. D. S., dos Santos, W. C., Rodrigues, V. P., Quidute, A. R. P., Magalhães, M., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.02.010 · Cited by 4
Goyal, A., Attri, B., Gupta, Y., Kalaivani, M., Jyotsna, V. P., & Tandon, N. (2023) · Clinical Endocrinology · doi:10.1111/cen.14920 · Cited by 6
“cortisol (LNSC) as the initial screening tests, which complement each other in the diagnostic work‐up of CS.(3) Measurement of cortisol in saliva samples collected at late‐night”
BackgroundMethodInfluentialRenal Hypokalemia: An Endocrine Perspective
Culver, S. A., Suleman, N., Kavuru, V., & Siragy, H. M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae201 · Cited by 9
Hashemi‐Madani, N., Cheraghi, S., Emami, Z., et al. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01619-z · Cited by 4
“The diagnosis of CD was based on clinical features and biochemical criteria [11].”
MethodMotomura, Y., Urai, S., Bando, H., Yamamoto, M., Suzuki, M., Yamamoto, N., Iguchi, G., Ogawa, W., & Fukuoka, H. (2024) · Endocrine · doi:10.1007/s12020-024-03935-9 · Cited by 5
“…fi c features (shown as atypical in Japan Endocrine Society ’ s guideline), including hypertension, menstrual abnormalities, acne, hirsutism, peripheral edema, glucose metabolism impairment, osteoporosis, pigmentation (which is not expected in patients with ACS), and mental abnormalities [1, 8, 12].”
BackgroundInfluentialHepşen, S., Gul, U., Bostan, H., Akhanlı, P., Sencar, M. E., Kızılgül, M., Ünsal, İ. Ö., & Çakal, E. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01598-0 · Cited by 6
“The current guidelines recommend screening adult patients who display clinical conditions such as hypertension and osteoporosis not typically associated with their age, multiple clinical features consistent with CS, as well as patients with adrenal adenoma [3].”
BackgroundNath, B., Dorairaj, P., Nair, T., Aurora, A., Sengupta, S., & Sharma, U. P. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.0877 · Cited by 10
High recovery rate of adrenal function after successful surgical treatment of Cushing’s syndrome
van de Ven, A. C., van Houten, P., Grevers, L., Timmers, H. J. L. M., van Lindert, E., Langenhuijsen, J. F., & Netea-Maier, R. T. (2025) · Endocrine Connections · doi:10.1530/ec-24-0612 · Cited by 6
Hickey, C., Gueron, B., Schmidt, F., Tyas, E., Binowski, G., & Pivonello, R. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03229-0 · Cited by 5
“Patients also experience several chronic comorbid conditions, including cardiovascular diseases, metabolic disorders, and musculoskeletal and neuropsychiatric disturbances [6, 8].”
Yin, X., Adelaars, S., Peri, E., Pelssers, E., den Toonder, J. M. J., Bouwman, R. A., van de Kerkhof, D., & Mischi, M. (2025) · Sensors · doi:10.3390/s25154551 · Cited by 6
“In addition, while saliva-and urine-based diagnostic methods can provide valuable diagnostic information, they may have limitations in detecting complex cases, particularly in identify the underlying causes of Cushing’s syndrome in complex cases [1,2].”
Moloney, K. J., Mercado, J. U., Ludlam, W. H., & Broyles, F. E. (2016) · Clinical Case Reports · doi:10.1002/ccr3.647 · Cited by 4
“The variability of screening tests is one factor contributing to the reduced reliability of diagnosis of CD [1, 2].”
BackgroundMethodInfluentialLi, L., Yang, G., Dou, J., Gu, W., Lv, Z., Lu, J., & Mu, Y. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-101236 · Cited by 4
“In order to determine the presence of SHC, the same 4 endocrinological tests used for the diagnosis of overt Cushing’s syndrome are employed [9, 10]: reduced cortisol suppression after the 1-mg overnight dexamethasone suppression test (DST), low morning ACTH level, high 24-h urinary free cortisol (UFC), and high midni…”
BackgroundMethodAn unusual manifestation of olfactory neuroblastoma
Batacchi, Z. O., Andeen, N. K., & Trikudanathan, S. (2018) · BMJ Case Reports · doi:10.1136/bcr-2017-221661 · Cited by 4
Wilson, J. B., Zopey, M., Augustine, J. M., Schaffer, R. L., Chiang, M., & Friedman, T. C. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1253-2854 · Cited by 4
“Signs and symptoms of hypercortisolism include central obesity with rapid weight gain, striae, hypertension, fatigue, and sleep disturbances [5].”
BackgroundHypercortisolism in patients with cholestasis is associated with disease severity
Theiler‐Schwetz, V., Schlager, H., Obermayer-Pietsch, B. M., Stojaković, T., Fauler, G., Fickert, P., & Zollner, G. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-02045-4 · Cited by 5
“Accordingly, further testing for Cushing’s syndrome would have been considered only in patients with unusual features for age, patients with multiple and progressive features, particularly those who are more predictive of Cushing’s syndrome or patients with adrenal incidentaloma [19].”
BackgroundMalygina, A. A., Belaya, Z. E., Nikitin, A. G., Koshkin, P. A., Sitkin, I. I., Лапшина, А. М., Магомедовна, Х. П., Lutsenko, A. S., Аршалуйсовна, Т. Д., & Mel'nichenko, G. A. (2021) · Problems of Endocrinology · doi:10.14341/probl12817 · Cited by 4
Gong, Z., QIN, Y., Wang, Y., Liu, X., Jiang, L., Cui, D., & Zhang, M. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109994 · Cited by 8
Lam-Chung, C., & Ramos, D. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1075785 · Cited by 4
Deveci, O., Karaca, Z., Tanrıverdi, F., Deveci, K., Hacıoğlu, A., Ünlühızarcı, K., & Keleştimur, F. (2022) · Annales d Endocrinologie · doi:10.1016/j.ando.2022.11.003 · Cited by 4
Primary bilateral macronodular adrenal hyperplasia: A series of 32 cases and literature review
Castro, M. A., & Reincke, M. (2023) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2022.12.010 · Cited by 7
Sulu, C., Şenel, G. B., Koca, O., Alaylıoğlu, M., Demir, A. N., Durcan, E., Gezen‐Ak, D., Dursun, E., Konukoğlu, D., Özkaya, H. M., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02133-0 · Cited by 4
“The inclusion criteria for the CD group were as follows: (i) age between 18 and 65 years, (ii) diagnosis of active CD [26], and (iii) consent to participate.”
Steroid profiling in adrenal disease
Mu, D., Sun, D., Qian, X., Ma, X., Qiu, L., Cheng, X., & Yu, S. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117749 · Cited by 6
Erkan, B., Bayındır, M., Akpınar, E., Tanrıverdi, O., Haşimoğlu, O., Postalcı, L. Ş., Acarer, D., Uzman, D. T., Doğanşen, S. Ç., Çakır, İ., et al. (2024) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2023.0100 · Cited by 7
“CD was diagnosed based on unsuppressed cortisol levels (>1.8 µg/dL) following the 1-mg dexamethasone suppression test, high levels of urinary free cortisol, or late night salivary cortisol and plasma ACTH levels >20 pg/mL 28) .”
BackgroundInfluentialBryk, A. H., Minasyan, M., Świątkowska−Stodulska, R., Undas, A., Hubalewska–Dydejczyk, A., Webb, S. M., Valassi, E., & Gilis‐Januszewska, A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1350010 · Cited by 7
Salivary cortisol and cortisone are stable after long-term storage
Imamovic, M., Bäcklund, N., Lundstedt, S., Brattsand, G., Aardal, E., & Dahlqvist, P. M. (2024) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2024.2403005 · Cited by 6
“The 1 mg dexamethasone suppression test is a well-established method for assessing the hypothalamic-pituitary-adrenal axis feedback system in the diagnostic work-up for Cushing’s syndrome [4].”
Doğanşen, S. Ç., Yılmaz, N., Selçukbiricik, Ö. S., Hekimsoy, Z., Canpolat, A. G., Topsakal, Ş., Yaylalı, G. F., Misiroglu, F., Gül, N., Üzüm, A. K., et al. (2024) · Endocrine · doi:10.1007/s12020-024-04004-x · Cited by 7
“As it is already known, SCLC is more common in males [5, 20, 33].”
InfluentialEvaluation of microRNAs as liquid biopsy markers in adrenocortical tumors
Mytareli, C., Kalotychou, V., Lafioniatis, A., Kaltsas, G., Zografos, G. N., Markou, Α., Papanastasiou, L., Fountas, A., Vassiliadi, D. A., Kassi, E., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1511520 · Cited by 5
Clinical Utility of Salivary Steroid Profiling for the Differential Diagnosis of Adrenal Diseases
Jung, K. Y., Park, S. Y., Lee, C., Ku, E. J., Lee, S., Kim, K., Kim, S. W., Rhee, Y., Lim, J. S., Chung, C. H., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf499 · Cited by 4
del Metabolismo, G. D. S. E. E. M., D’Aurizio, F., Tozzoli, R., Dorizzi, R. M., Brescia, V., Esposito, E., Fortunato, A., Giovanella, L., & Guzzaloni, G. (2015) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.1007/s13631-015-0088-0 · Cited by 4
“La Endocrine Society ha aggiornato nel 2008, con la partecipazione della European Society of Endocrinology, le linee guida per la diagnosi di sindrome di Cushing [10, 11].”
BackgroundInfluentialHypertension in Patients with Cushing’s Syndrome
Kantorovich, V., Koch, C. A., & Chrousos, G. P. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-548-4_3 · Cited by 6
The Investigation of Cushing Syndrome: Essentials in Optimizing Appropriate Diagnosis and Management
Juszczak, A., & Grossman, A. B. (2012) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2012.455 · Cited by 4
Adrenal Cortex Tumors and Hyperplasias
Pignatelli, D. (2011) · InTech eBooks · doi:10.5772/19108 · Cited by 6
“To establish the diagnosis of Cushing’s syndrome the following criteria should be met (Nieman et al., 2008): At least two of the first-line tests must be abnormal and conservative criteria should be used to interpret it to maximize sensitivity; for instance, in a patient with a symptomatic…”
BackgroundSharif-Alhoseini, M., Edward, R. L., & Rahimi‐Movaghar, V. (2012) · InTech eBooks · doi:10.5772/33824 · Cited by 5
“Fat also accumulates over the thorax and the abdomen, which becomes protuberant (33).”
BackgroundPitfalls in the diagnosis and differential diagnosis of C ushing's syndrome
Nieman, L. K. (2013) · Clinical Endocrinology · doi:10.1111/cen.12362 · Cited by 4
Self-citationBroder, M. S., Neary, M. P., Chang, E. Y., Cherepanov, D., Sun, G. H., & Ludlam, W. H. (2014) · Pituitary · doi:10.1007/s11102-014-0598-1 · Cited by 4
“The causes of endogenous Cushing’s syndrome are usually grouped into corticotropin-dependent (80–85 % of cases) and corticotropin-independent etiologies [1, 2].”
BackgroundNew options in the treatment of Cushing’s disease: a focus on pasireotide
Chevalier, N., & Poullot (2013) · Research and Reports in Endocrine Disorders · doi:10.2147/rred.s30972 · Cited by 4
“4–6 From early reports, it is well known that CD is associated with a very poor prognosis and can be lethal.”
Gastrointestinal Side Effects of Bisphosphonates Obscuring Vascular Disease
Grover, V., Licata, A. A., Kharlip, J., et al. (2010) · Endocrine Practice · doi:10.4158/ep.16.2.334 · Cited by 4
Palter, V. N., Devon, K. M., Hallet, J. I., Kulkarni, G. S., Law, C., & Urbach, D. R. (2016) · Springer eBooks · doi:10.1007/978-3-319-26276-5_1 · Cited by 5
“fo llo w in g [ 6 ] (i ni tia l a nd 1”
BackgroundFindling, J. W., & Raff, H. (2016) · Springer eBooks · doi:10.1007/978-3-319-45950-9_6 · Cited by 4
Self-citationAdrenal Pathologies During Pregnancy and Postpartum
St‐Jean, M., Bourdeau, I., & Lacroix, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814823-5.00025-8 · Cited by 5
Investigation of Cushing’s and subclinical Cushing’s syndromes using adrenocortical scintigraphy
Okada, Y., Matsushita, S., & Yamaguchi, K. (2021) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001391 · Cited by 4
Improving the Dexamethasone Suppression Test
Keevil, B. G. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab076 · Cited by 5
“8mg/dL (50 nmol/L) is the widely recommended cut-off that increases the diagnostic sensitivity of the test to approximately 95% (4).”
BackgroundEctopic Cushing’s Syndrome Secondary to Metastatic Paraganglioma
Daya, R., Wingfield, C., Sotshononda, P., Seedat, F., Bulbulia, S., Simmons, M. D., Louw, M., & Bayat, Z. (2021) · Case Reports in Endocrinology · doi:10.1155/2021/5593920 · Cited by 4
Castro, M. A., Mariño‐Sánchez, F., Fernández, A. G., Cancela, A. A., & Berrocal, V. R. (2021) · Neurocirugía · doi:10.1016/j.neucir.2021.07.004 · Cited by 6
Shah, N. Z., Malik, S., Sathyapalan, T., & Mohammed, K. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-244850 · Cited by 6
Noël, M., Fraissinet, F., Lefèbvre, H., Bénichou, J., Brunel, V., & Ziegler, F. (2021) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2021.11.016 · Cited by 5
Osilodrostat oral tablets for adults with Cushing’s disease
Martino, M., Aboud, N., Lucchetti, B., Salvio, G., & Arnaldi, G. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2044789 · Cited by 5
“Introduction Endogenous Cushing’s syndrome (CS) is a rare, multi-systemic condition resulting from chronic glucocorticoid excess [1].”
BackgroundChen, F., Xu, Q., Yue, W., Yu, X., & Shao, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.802453 · Cited by 4
Screening Tests for Hypercortisolism in Patients With Adrenal Incidentaloma
Ferreira, L., Oliveira, J. C., & Palma, I. (2018) · Journal of Endocrinology and Metabolism · doi:10.14740/jem510w · Cited by 5
Late-Night Salivary Cortisol for the Diagnosis of Cushing's Syndrome: A Meta-Analysis.
Carroll, T. B., Raff, H., & Findling, J. W. (2009) · Endocrine Practice · doi:10.4158/ep09023.orr · Cited by 5
Self-citationThe 1 mg overnight dexamethasone suppression test: a danger to the adrenal gland?
Vanek, C., & LORIAUX, L. D. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000752 · Cited by 5
Zhang, B., He, Q., Long, Y., Zhang, Y., Wang, X., Chen, Z., Liu, J., & Zhang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.962800 · Cited by 4
Enfermedad de Cushing en el embarazo y uso de cabergolina
Murillo, N. B., Ramacciotti, C. F., Fux-Otta, C., & Cecenarro, L. A. (2023) · Revista de la Facultad de Ciencias Médicas de Córdoba · doi:10.31053/1853.0605.v80.n1.37056 · Cited by 4
A Rare Cause of Cushing's Syndrome: an Adrenocorticotropic Hormone (ACTH)-Secreting Pheochromocytoma
Lopes, M. L. G., Bello, C., Carvalho, L., Limbert, C., & Duarte, J. S. (2023) · Cureus · doi:10.7759/cureus.37883 · Cited by 4
“Frequently, ECS produces higher levels of hypercortisolism than CD, resulting in more severe hypokalemia [1-3,10].”
BackgroundDiurnal Range and Intra-patient Variability of ACTH Is Restored With Remission in Cushing's Disease
Alvarez, R., Hogan, E. A., Asuzu, D. T., Wu, T., Oshegbo, G., McGlotten, R., Cortes, M. X., Hayes, C. P., Stratakis, C. A., Tatsi, C., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad309 · Cited by 5
Self-citationAldrete, K., & Shahla, L. (2024) · AACE Clinical Case Reports · doi:10.1016/j.aace.2024.08.002 · Cited by 4
Dalanhol, C. S., Scheid, C., & Merib, J. (2024) · Journal of Separation Science · doi:10.1002/jssc.70022 · Cited by 6
Gill, N., Sirizzotti, N., Johnson, D. W., Joubert, G. I., Kucey, A. S., Tieu, A., Urquhart, B. L., Columbus, M. P., Lim, R. K., Rieder, M. J., et al. (2017) · Pediatric Emergency Care · doi:10.1097/pec.0000000000001142 · Cited by 4
“It is recommended for the evaluation of glucocorticoid secretion after a dexamethasone suppression test.(22) However, normative spot urinary values have not been described in children.”
BackgroundA pheochromocytoma case diagnosed as adrenal incidentaloma
Vurallı, D., Kandemir, N., Clark, G. R., Orhan, D., Alikaşifoğlu, A., Gonc, N. E., Ekinci, S., & Özön, A. (2017) · The Turkish Journal of Pediatrics · doi:10.24953/turkjped.2017.02.015 · Cited by 4
“7 pg/ml (5-33) Aldosterone: 80 pg/ml (30-313)”
Korkmaz, Ö. P., Karayel, B., Korkmaz, M., Haliloglu, O., Sahin, S., Durcan, E., Oren, M. M., & Kadioglu, P. (2019) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2019.195 · Cited by 4
“8 μg/dL during low-dose 1 mg the LDDST were identified as having biochemical remission after surgery (17).”
BackgroundMethodCushing Disease Masquerading as Glaucoma
Tsushima, Y., Munshi, L. B., Taneja, C., & Kim, S. (2019) · AACE Clinical Case Reports · doi:10.4158/accr-2019-0097 · Cited by 4
Recurrent cardiac and skin myxomas along with acromegaly: A case report of carney complex.
Shirinpour, Z., Farhangiyan, Z., Akiash, N., & Rashidi, H. (2020) · PubMed Central · doi:10.22122/arya.v16i3.2080 · Cited by 3
Libianto, R., Yang, J., & Fuller, P. J. (2021) · Australian Journal of General Practice · doi:10.31128/ajgp-09-20-5619 · Cited by 4
Klein, J., Vuguin, P. M., & Hyman, S. J. (2014) · Pediatrics in Review · doi:10.1542/pir.35-9-405 · Cited by 7
Krysiak, R. G., Kędzia, A. W., & Okopień, B. (2012) · PubMed · doi:10.2143/acb.67.1.2062623 · Cited by 7
Differential diagnostics of adrenal incedentaloma
Kuznetsov, N. S., Beltsevich, D. G., Vanushko, V. E., Soldatova, T. V., Ремизов, О. В., Kats, L. E., & Lysenko, M. A. (2011) · Endocrine Surgery · doi:10.14341/2306-3513-2011-1-5-16 · Cited by 6
Kitamura, T., Otsuki, M., Tamada, D., Tabuchi, Y., Mukai, K., Morita, S., Kasayama, S., Bando, Y., Shimomura, I., & Koga, M. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.09.007 · Cited by 4
“Autonomic and inappropriate cortisol secretion is mostly caused by ACTH producing pituitary adenoma and cortisol producing adrenal adenoma [13].”
Background
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.